These inhibitors attenuate the proliferation of MYCN-expressing NB cells and some of them are being tested in clinical trials; however, the development of resistance, toxicity, MDM2 accumulation, and the need for wild-type p53 make the trials challenging78. This evidence concerns the gene TP53 and neuroblastoma.